2.02

0.98% -0.02

After Hours: 1.96 -0.06 -2.97%

MAIA Biotechnology Inc (MAIA)

Overview News Price History Discussions Forecast

MAIA Biotechnology Inc stock is traded at $2.02, with a volume of 119.72K. It is down -0.98% in the last 24 hours and down -9.42% over the past month. MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. MAIA Biotechnology, Inc. was incorporated in 2018 and is headquartered in Chicago, Illinois.

Previous Close:

$2.04

Open:

$2.02

24h Volume:

119.72K

Relative Volume:

0.74

Market Cap:

$51.17M

Revenue:

Net Income/Loss:

$-25.94M

P/E Ratio:

-1.2866

EPS:

-1.57

Net Cash Flow:

$-15.79M

1W Performance:

+1.00%

1M Performance:

-9.42%

6M Performance:

-41.11%

1Y Performance:

+100.00%

1-Day Range:

$1.92

$2.16

1-Week Range:

$1.88

$2.63

52-Week Range:

$0.98

$5.99

MAIA Biotechnology Inc Stock (MAIA) Company Profile

Name

MAIA Biotechnology Inc

Sector

Healthcare (1176)

Industry

Biotechnology (673)

Phone

312 416 8592

Address

444 West Lake Street, Suite 1700, Chicago

Employee

Twitter

Next Earnings Date

Latest SEC Filings

MAIA's Discussions on Twitter

Compare MAIA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MAIA MAIA Biotechnology Inc	2.02	51.17M	0	-25.94M	-15.79M	-1.38
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

MAIA Biotechnology Inc Stock (MAIA) Latest News

Dec 19, 2024

MAIA Biotechnology Directors Show Strong Confidence with $573K Personal Investment in Private Placement - StockTitan

Dec 19, 2024

Dec 16, 2024

MAIA Biotech Secures FDA Rare Pediatric Disease Status for Novel Brain Cancer Drug, Eyes $100M Voucher - StockTitan

Dec 16, 2024

Dec 14, 2024

Stan Smith Acquires 25,000 Shares of MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Stock - MarketBeat

Dec 14, 2024

Maia Biotechnology director Stan Smith acquires $46,800 in stock - Investing.com India

Dec 14, 2024

Dec 13, 2024

Maia Biotechnology director Stan Smith acquires $46,800 in stock By Investing.com - Investing.com South Africa

Dec 13, 2024

Maia Biotechnology director Ramiro Guerrero buys $99,998 in stock - Investing.com

Dec 13, 2024

Maia Biotechnology director Ramiro Guerrero buys $99,998 in stock By Investing.com - Investing.com UK

Dec 13, 2024

Dec 10, 2024

MAIA Biotechnology, Inc. announced that it expects to receive $0.949785 million in funding - Marketscreener.com

Dec 10, 2024

MAIA Biotechnology announces $950,000 private placement - MSN

Dec 10, 2024

Dec 09, 2024

MAIA Biotechnology Secures $950K Private Placement to Advance THIO Clinical Trials - StockTitan

Dec 09, 2024

Dec 04, 2024

MAIA Biotech expands phase 2 trial for lung cancer treatment By Investing.com - Investing.com South Africa

Dec 04, 2024

Dec 03, 2024

MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung Cancer - XM

Dec 03, 2024

MAIA Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 12, 2024

Nov 11, 2024

THIO Combo Shows Enduring Activity in Advanced Non–Small Cell Lung Cancer - Cancer Network

Nov 11, 2024

Nov 09, 2024